John P. Diaz, MD, discusses how meetings on gynecologic oncology provide advantages for everyday physicians to keep track of the latest updates on the treatment landscape.
John P. Diaz, MD, the chief of Gynecologic Oncology, lead physician for Clinical Trials in Gynecologic Oncology at MCI, and chief of the Center of Excellence in Minimally Invasive Gynecologic Surgery, Baptist Health South Florida, discusses the advantages of meetings on gynecologic oncology for the everyday physician.
In particular, Diaz discusses the Miami Cancer Institute Women’s Cancer Symposium, which was held on April 21, 2023, and how a meeting like this can help everyday physicians make sense of the latest developments in the field of gynecologic oncology.
During this year's meeting, experts highlighted new updates in maintenance therapy for patients with ovarian cancer, new surgical techniques for patients with endometrial cancer, and more in order to provide information on the latest developments across the gynecologic oncology space.
0:08 | This meeting really is geared for physicians. As I've said, we've had great advances in the treatment of gynecologic malignancies, and for the everyday practicing medical oncologists it can be difficult to keep up with the latest and greatest [developments], and so, that's what we've tried to do with this meeting. There have been advances in the maintenance therapy for [patients with] ovarian cancer. There have been advances in the treatment of [patients with] endometrial cancer.
0:28 | There have [also] been advances in the surgical management [of these patients], so we have Dr. Nadeem R. Abu-Rustum from [Memorial Sloan Kettering Cancer Center], as well as Dr. Martin Martino who are coming to talk about some of the surgical advances in endometrial cancer. And as I said, Dr. Lesley Randall is going to come talk about some of the advances in cervical cancer. This is a great way to get all these experts in the field together and really update us in the treatment of women who are suffering from gynecologic malignancies.